Recent

% | $
Quotes you view appear here for quick access.

NUO THERAPEUTİCS, AŞ Message Board

  • philphillyguy philphillyguy Aug 14, 2013 7:38 AM Flag

    Sorry I rather listen to...

    Martin Rosendale CEO
    Ken Fields COO
    The FDA
    Arthrex
    National Heart, Lung, and Blood Institute (NHLBI)
    183 testimonials to Congress
    A letter from the Congressional Black Caucus praising PRP
    Duke University Medical Center
    Johns Hopkins University Center
    University of Miami/Jackson Memorial Hospital
    Dileep Yavagal, M.D
    Joshua M. Hare, M.D., Director of the Interdisciplinary Stem Cell Institute
    Frost & Sullivan
    Zacks Research
    Henry McCusker
    Life Science Advisors
    John Paul DeJoria 4,021,726(2012) John Paul DeJoria
    Increased his position to (2013) 7,125,974
    Intersouth Partners 2,737,580 4.93
    CNF Investments II, LLC 634,679 1.14
    HARBERT VENTURE PARTNERS LLC 423,119 0.76
    Aurora Funds Limited 253,872 0.46
    TULLIS DICKERSON CAPITAL FOCUS III, L.P. 126,936 0.23
    New Markets Growth Fund, LLC 42,312 0.08

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • luv this really

    • not when you have koko...LMAO!

      Sentiment: Strong Buy

    • great bunch there

      Sentiment: Strong Buy

    • taddickson333@gmail.com taddickson333 Aug 28, 2013 4:52 PM Flag

      Just picked up a few Shares... Really looks like this has potential to move forward after the Phase III Trials and I like what they have done with the added contracts and partnerships.

      Sentiment: Buy

    • Very interesting Cytomedix study underway led by the National Institute of Health. Impressive research sites…
      National Institutes of Health to participate in the Cardiovascular Cell Therapy Research Network, a consortium that also includes Stanford University, Texas Heart Institute, the University of Florida, the University of Miami, Minneapolis Heart Institute Foundation and Indiana University.

      Stem cell trial at University of Louisville seeks participants
      Posted on August 14, 2013 by Laura Ungar

      A network of cell therapy centers that includes the University of Louisville is enrolling patients in a clinical trial testing an adult stem cell treatment for peripheral arterial disease, in which plaque builds up in the arteries and blocks blood flow to the legs.

      Last year, U of L’s Dr. Roberto Bolli was awarded $3.4 million over seven years from the National Institutes of Health to participate in the Cardiovascular Cell Therapy Research Network, a consortium that also includes Stanford University, Texas Heart Institute, the University of Florida, the University of Miami, Minneapolis Heart Institute Foundation and Indiana University.

      Bolli will lead the study at U of L. The goal for the network sites is to collectively enroll 80 patients in one year. Trial participants must be 40 or older and have PAD with “claudation,” charactized by pain, numbness, aching, cramping or heaviness in the leg muscles.

      In the study, the treatment group will recieve stem cells taken from the patient’s own bone marrow and processed through a technology owned by the company Cytomedix Inc. There will also be a group receiving placebo for comparison. Study participants will be followed for one year

      Sentiment: Strong Buy

    • no one selling just buying....MMMMMMMMMMMMMmmmmmmmmmmmmmmm

      Sentiment: Strong Buy

    • Joshua M. Hare, M.D., Director of the Interdisciplinary Stem Cell Institute
      Frost & Sullivan
      Zacks Research
      Henry McCusker
      Life Science Advisors
      John Paul DeJoria 4,021,726(2012) John Paul DeJoria
      Increased his position to (2013) 7,125,974
      Intersouth Partners 2,737,580 4.93
      CNF Investments II, LLC 634,679 1.14
      HARBERT VENTURE PARTNERS LLC 423,119 0.76
      Aurora Funds Limited 253,872 0.46
      TULLIS DICKERSON CAPITAL FOCUS III, L.P. 126,936 0.23
      New Markets Growth Fund, LLC 42,312 0.08

    • WOW!,,,DId I say WOW!